Biotech Regulatory Affairs Consulting

Innovative therapies such as cell and gene treatments, CAR-T, monoclonal antibodies and peptides are reshaping the future of medicine. Yet, their path to market in China and across Asia Pacific is defined by intricate, rapidly evolving regulatory frameworks. At Cisema, we specialize in guiding biotech companies through these complexities with precision and confidence. Our regulatory affairs consulting is purpose-built for novel therapies.  

From early-stage clinical trial applications to post-market lifecycle management, our team delivers strategic support grounded in decades of experience and deep regional insight. We help you align with regulatory expectations, avoid costly delays, and accelerate market access across APAC, including China.

Success in Asia Pacific demands country-specific adaptation, localized regulatory intelligence, proactive engagement with regulatory agencies and tailored submission strategies. Our team works as an extension of your team, streamlining approvals, mitigating risks, and ensuring compliance every step of the way.

Biotech Regulatory Affairs Services in China and APAC
Biotech Regulatory Affairs Consulting

Our Biotech Regulatory Affairs Services in China & Asia Pacific

Strategic Regulatory Expertise

We support biotechnology innovators and investors by navigating the complexities of regulatory affairs with precision and foresight. Whether you're preparing for market authorization, engaging with global health authorities, or managing compliance across regions, our team develops tailored strategies that align with your product goals and regulatory milestones.

Due Diligence & Partnering

Whether you're acquiring, licensing, or entering strategic partnerships, we provide targeted regulatory insight to support your decision-making. Our senior team helps assess risks, identify gaps, and propose mitigation strategies, ensuring confidence before you commit.

Regulatory Strategy & Agency Engagement

We help you develop a regulatory roadmap that supports your product’s lifecycle and maximizes agency alignment. Our services include:

Development of regional regulatory strategies tailored to your product type and local requirements
Early engagement planning with regulatory authorities
Briefing book preparation and meeting strategy
Representation in agency meetings to ensure clarity and alignment.

Marketing Authorization

Our joined-up approach ensures your submission is efficient, compliant, and positioned for success across diverse regulatory landscapes.

Early engagement with regional authorities
Gap analysis and submission strategy
Authoring, preparation and publishing of CTD dossiers
Submission and coordination during agency review and response.

Our joined-up approach ensures your submission is efficient, compliant, and positioned for success across diverse regulatory landscapes.

Pharmacovigilance

Pharmacovigilance (PV) is more than compliance; it’s a commitment to patient safety and product integrity. We offer flexible PV solutions from tactical support to strategic partnerships. For more details, visit our dedicated PV page.

Quality Management & Compliance

We help you build and maintain a robust Quality Management System (QMS) aligned with GxP standards. Our services include gap analysis, SOP development, inspection readiness, and remediation planning, tailored to your development stage and business model. Visit our dedicated Quality page.

Why Work with Cisema?

Deep Scientific & Regulatory Expertise in Advanced Biotech Products

We understand the complexity of next-generation therapies. Our consultants bring experience with cell-based, gene-edited, and peptide-based products, offering practical insight to support compliant and efficient development.

Local Regulatory Know-how

With teams based across Asia Pacific, we guide you through the nuances of country-specific regulations, including clinical requirements, quality documentation, and procedures for marketing authorizations for novel therapies.

Integrated Lifecycle Support

From applications for clinical trials to marketing approval and beyond, we provide continuous support to keep your product aligned with evolving regulatory requirements and expectations across the Asia Pacific region.

Proactive Risk Management & Regulatory Foresight

Our regulatory affairs professionals minimize delays and optimize outcomes with strategic planning, proactive engagement with health authorities, and a strong focus on regulatory compliance.

Role of a China Agent

Frequently Asked Questions

As early as possible. Early planning is critical to align with country-specific regulatory frameworks. Strategic planning from the outset ensures smoother clinical development and faster market access.

In many cases, yes. However, bridging studies or supplemental local data may be required. We help you assess data acceptability, identify gaps, and develop region-specific strategies to meet regulatory expectations.

New modalities such as CAR-T or gene therapies present unique regulatory challenges ranging from complex manufacturing and product traceability to long-term safety monitoring. We stay on top of evolving regulations to ensure your submissions are robust and compliant.

Yes. Most jurisdictions mandate a local legal representative for regulatory filings and authority communications. Cisema provides agent services across the region, ensuring full compliance and seamless engagement with regulators.

Request a Proposal from Our Biotech Team

Let Cisema help turn your plans into reality.

Angebot anfordern

Explore Related Services

Clinical Development 
Services

Drive successful market entry and growth with confidence. Our product development experts support biotech and pharmaceutical companies in streamlining drug development, accelerating approvals, and achieving commercialization through tailored strategies, clinical insights, and end-to-end compliance solutions.

Mehr erfahren

Health Economics & Market Access

Accelerate access across China and Asia Pacific with confidence. Our market access consulting experts help life sciences companies optimize patient access, navigate pricing and reimbursement challenges, and enable commercial success through real world evidence, health economics, and tailored access strategies.

Mehr erfahren

Pharmacovigilance

Ensure drug safety and regulatory compliance across China and Asia Pacific with confidence. Our pharmacovigilance consulting experts support life sciences companies in managing risks, meeting evolving safety requirements, and maintaining market authorization through end-to-end PV solutions tailored to local regulations.

Mehr erfahren

Quality Management & Compliance

Ensure regulatory excellence across China and Asia Pacific with confidence. Our quality management and compliance experts help life sciences companies strengthen GxP systems, streamline audits, and maintain inspection readiness to safeguard market access and operational performance.

Mehr erfahren

Aktuelle Einblicke

Mehr anzeigen

CDE Releases 2025 Annual Report on the Progress of Clinical Trials for New Drug Registration in China

Explore the latest data on China’s clinical research landscape, including record trial activity, shorter development timelines, and emerging R&D trends.

August 3, 2026
CDE Releases 2025 Annual Report on the Progress of Clinical Trials for New Drug Registration in China

China Targets 65 Drugs in Its 12th National Procurement Round

The 12th national VBP round introduces tighter quality, manufacturing, and IP requirements that pharmaceutical companies must meet to compete.

August 3, 2026
China Targets 65 Drugs in Its 12th National Procurement Round

China CDE Defines Classification Rules for Cell & Gene Therapy Drugs

New NMPA CDE guidelines define CTMP and GTMP boundaries, affecting development strategy, CMC planning, and regulatory engagement in China.

August 3, 2026
China CDE Defines Classification Rules for Cell & Gene Therapy Drugs

China's 2026 Essential Medicines Adds More Innovative Drugs

China's updated National Essential Medicines List expands access to innovative medicines, creating new opportunities and strategic considerations for pharmaceutical companies.

August 3, 2026
China's 2026 Essential Medicines Adds More Innovative Drugs
A middle-aged man with glasses is looking down thoughtfully as he pours medication or pills from a small white bottle with a yellow label into his open palm.

China NMPA Expands Priority Review for Chemical API Marketing Authorization Applications

China's NMPA expands priority review eligibility for chemical API marketing authorization applications, supporting domestic API production and drug supply.

August 3, 2026
China NMPA Expands Priority Review for Chemical API Marketing Authorization Applications
Chemical API Manufacturing

China Releases 2026 Anti-Corruption Priorities for Pharmaceutical Sales & Medical Services

China's 2026 enforcement priorities expand scrutiny of pharmaceutical sales, procurement, pricing, data security, and compliance across the healthcare sector.

August 3, 2026
China Releases 2026 Anti-Corruption Priorities for Pharmaceutical Sales & Medical Services
Zurück
Zurück

Get in Touch with Our Biotech Consultants

Speak with our team to explore how our regulatory affairs services can help your regulatory affairs managers bring products to market across Asia Pacific.

Angebot anfordern